Kindred Biosciences
(KIN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,796 | -61,389 | -49,690 | -30,879 | -22,499 |
| Depreciation Amortization | 4,996 | 2,110 | 626 | 637 | 429 |
| Accounts receivable | 352 | -20 | -903 | 0 | 0 |
| Accounts payable and accrued liabilities | -1,169 | 1,838 | 277 | 1,280 | -710 |
| Other Working Capital | -4,526 | -4,693 | -2,282 | 3,130 | -341 |
| Other Operating Activity | 12,286 | 5,812 | 6,937 | 3,954 | 4,340 |
| Operating Cash Flow | $-9,857 | $-56,342 | $-45,035 | $-21,878 | $-18,781 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 9,329 | -39,393 | 30,275 | 3,252 | 6,266 |
| PPE Investments | -3,556 | -8,423 | -13,671 | -5,920 | -952 |
| Investing Cash Flow | $5,773 | $-47,816 | $16,604 | $-2,668 | $5,314 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 19,181 | N/A | N/A | N/A |
| Common Stock Issued | 584 | 45,154 | 50,167 | 52,672 | 162 |
| Other Financing Activity | -866 | -493 | -247 | 0 | 0 |
| Financing Cash Flow | $-282 | $63,842 | $49,920 | $52,672 | $162 |
| Beginning Cash Position | 15,986 | 56,302 | 34,813 | 6,687 | 19,992 |
| End Cash Position | 11,620 | 15,986 | 56,302 | 34,813 | 6,687 |
| Net Cash Flow | $-4,366 | $-40,316 | $21,489 | $28,126 | $-13,305 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,857 | -56,342 | -45,035 | -21,878 | -18,781 |
| Capital Expenditure | -3,638 | -8,428 | -13,919 | -5,920 | -952 |
| Free Cash Flow | -13,495 | -64,770 | -58,954 | -27,798 | -19,733 |